Ravi B. Parikh: Comparing Survival Outcomes With BGS vs FBT in Advanced NSCLC
Ravi B. Parikh/LinkedIn

Ravi B. Parikh: Comparing Survival Outcomes With BGS vs FBT in Advanced NSCLC

Ravi B. Parikh, Director of Human-Algorithm Collaboration Lab (HACLab) and Associate Professor at Winship Cancer Institute of Emory University, shared on LinkedIn:

“New in Journal of the National Comprehensive Cancer Network (NCCN) led by Patricia Santos: Broad-based genomic sequencing (BGS) (NGS) has wide uptake in NSCLC. This is good. But there is mixed population-evidence on survival benefits associated with real-world uptake. We compared survival associated with BGS vs focused biomarker testing (FBT) among 35,060 patients with advanced NSCLC across US oncology practices from 2016 to 2022.

In propensity score-matched analyses, upfront BGS prior to first-line systemic therapy was associated with modest but meaningful improvements in median progression-free survival (6.4 vs 6.0 months; adjusted HR, 0.96) and median overall survival (16 vs 14 months; adjusted HR 0.91). This was a function of therapeutic selection: BGS recipients demonstrated significantly higher rates of overall biomarker positivity (60% vs 22%) and subsequent receipt of matched targeted therapy (19% vs 16%). The survival advantage was concentrated in patients with nonsquamous histologies, whereas no significant association was observed in the second-line setting.

These findings provide some of the best population-level support for national clinical guidelines that advocate for comprehensive upfront genomic profiling at the time of an NSCLC diagnosis. As BGS and targeted therapies increase in other cancers, we expect simila rfindings. However, payer coverage remains heterogeneous, with variations in test requirements, panel size thresholds, and line-of-therapy restrictions. Furthermore, disparities in BGS uptake among publicly insured patients highlight the need for policy interventions to ensure equitable access to genetic sequencing.”

Title: Broad-Based Genomic Sequencing and Survival Outcomes in Advanced Non–Small Cell Lung Cancer: 2016–2022

Authors: Patricia Mae G. Santos, Lillian A. Boe, Kawther Al Ksir, Ticiana Leal, Daniel R. Gomez, Ravi B. Parikh

Read the Full Article on Journal of the National Comprehensive Cancer Network 

You can also read: International Lung Cancer Summit 2026: From Molecular Targets to the Next Era of Precision Thoracic Oncology

Ravi B. Parikh: Comparing Survival Outcomes With BGS vs FBT in Advanced NSCLC